After numerous twists and turns Pharmamar will no longer have to wait for next year’s binary outcome of the pivotal Atlantis trial before filing its small-cell lung cancer project Zepsyre. Instead, based on the just-revealed result of a call with the US FDA, filing for accelerated approval will take place in the fourth quarter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,